A novel nomogram based on log odds of positive lymph nodes to predict survival for non-metastatic gallbladder adenocarcinoma after surgery

Jiang, Shimin; Zhang, Junwei; Zhang, Lei; Xu, Yiyao; Zhao, Haitao; Sang, Xinting; Lü, Xin

doi:10.1038/s41598-022-20933-x

Cited by 12 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifthly, a precise prognostic nomogram would be selected through evaluating the performance, including discrimination (i.e., concordance index (C-index) based on bootstrap, time-dependent area under the curve (AUC)), calibration (i.e., calibration curve), and net benefit (i.e., decision curve analysis (DCA)). C-index and time-dependent AUC values exceed 0.7 suggested a reasonable estimation 28 . Accordingly, a web-based dynamic nomogram would be built as a decision-making tool.…”

Section: Discussionmentioning

confidence: 86%

Predicting hospital readmissions in patients receiving novel-dose Sacubitril/Valsartan therapy: A competing-risk, causal mediation analysis

Hou¹,

Hao²,

Sun³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The effects of novel-dose Sacubitril/Valsartan (S/V) in patients with heart failure (HF) in the real world have not been adequately studied. We examined the risk for all-cause re-admission in the patients with HF taking novel-dose S/V and the possible mediator role of left ventricular reverse remodeling (LVRR). Methods and Results: There were 464 patients recruited from December 2017 to September 2021 in our hospital with a median follow-up of 660 days (range, 17-1494). Model 1 and 2 were developed based on the results of univariable competing risk analysis, least absolute shrinkage and selection operator approach, backward stepwise regression and multivariable competing risk analysis. The internal verification (data-splitting method) indicated that Model 1 had better discrimination, calibration, and clinical utility. The corresponding nomogram showed that patients aged 75 years and above or taking the lowest-dose S/V (≤50mg twice a day), or diagnosed with ventricular tachycardia, or valvular heart disease, or chronic obstructive pulmonary disease, or diabetes mellitus were at the highest risk of all-cause readmission. In the causal mediation analysis, LVRR was considered as a critical mediator that negatively affected the difference of novel-dose S/V in readmission. Conclusions: A significant association was detected between novel-dose S/V and all-cause readmission in HF patients, in part negatively mediated by LVRR. The web-based nomogram could provide individual prediction of all-cause readmission in HF patients receiving novel-dose S/V. The effects of different novel-dose S/V are still needed to be explored further in the future.

show abstract

Section: Discussionmentioning

confidence: 86%

Predicting hospital readmissions in patients receiving novel-dose Sacubitril/Valsartan therapy: A competing-risk, causal mediation analysis

Hou¹,

Hao²,

Sun³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Two-tailed P values < 0.05 were considered statistically signi cant. The overall patients were divided into the training cohort (n = 970) and validation cohort (n = 417) with a proportion of 7:3 randomly using the "Random Samples and Permutations" function in R (Liu, Huang et al 2020, Jiang, Zhang et al 2022). The training cohort was utilized for model construction, while the validation cohort was employed for model validation.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a web-based nomogram for predicting cancer-specific survival in patients with intrahepatic cholangiocarcinoma: A SEER database analysis

Liu

Jiang

Zhang

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Intrahepatic cholangiocarcinoma (ICCA) is one of the most malignant tumors of the biliary system. This study aims to develop and validate a prognostic nomogram that can estimate the probability of 1-, 3- and 5-year cancer-specific survival (CSS) for ICCA patients. Methods Clinical data of 1387 patients diagnosed with ICCA between 2010 and 2017 from the Surveillance, Epidemiology, and End Results database were analyzed. 970 patients were set as the training cohort to construct the nomogram while the rest 417 patients were set as the validation cohort. To compare the efficacy to predict 1-, 3-, and 5-year CSS of the nomogram with the 8th edition of the American Joint Committee on Cancer (AJCC) staging system, we evaluated the Harrell’s index of concordance (C-index), area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA) in both cohorts. Meanwhile, a dynamic network-based nomogram was published. Results Age, sex, AJCC T stage, AJCC N stage, AJCC M stage, surgery status, and tumor grade were selected as independent prognostic risk factors to build the nomogram. The C-index in the training and validation cohorts were 0.726 and 0.711 respectively. The AUCs in the training cohort for 1-, 3-, and 5-year CSS prediction were 0.787, 0.828, and 0.843. In the validation cohort, the AUCs were 0.776, 0.817, and 0.782. All of the AUCs of the nomogram for 1-, 3-, and 5-year CSS prediction performed better than the AJCC staging system. Moreover, the DCA analysis demonstrated the net benefit of the nomogram was better. The survival analysis showed the survival rate of patients classified as high-risk based on the nomogram score was significantly lower compared to those categorized as low-risk (p < 0.0001). Conclusions An accurate and convenient nomogram was established to assist clinicians in making more personalized prognosis predictions for ICCA patients.

show abstract

“…At present, the survival prediction for patients with GBA is mainly based on the eighth edition of the staging guidelines for tumor-node-metastasis (TNM) defined in the American Joint Committee on Cancer (AJCC) staging system ( 9 , 10 ). However, staging can only be performed after surgery, for which only a minority of patients with GBA are eligible ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Metabolic parameters of pretreatment 2-[18F]fluoro-D-glucose positron emission tomography for prognosis in patients with gallbladder adenocarcinoma: a cohort study

Li,

Dong,

Pan

et al. 2024

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background The incidence of gallbladder adenocarcinoma (GBA) is relatively low, yet it exhibits a high degree of malignancy and a significantly low 5-year survival rate. The aim of this study was to investigate the prognostic value of pretreatment 2-[ 18 F]fluoro-D-glucose positron emission tomography {2-[ 18 F]FDG PET} parameters in predicting outcomes for patients with GBA. Methods In total, 67 patients with GBA who underwent 2-[ 18 F]FDG PET/computed tomography (CT) before treatment were retrospectively analyzed at Chinese PLA General Hospital from January 2012 to June 2022. All patients were diagnosed by pathology, and their baseline characteristics and clinical data were collected. The metabolic PET parameters of the primary and metastatic lesions were measured, including the maximum and average standardized uptake values (SUVs), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). The prognostic significance of metabolic parameters and other clinical variables was assessed using Cox proportional hazards regression models. Differences in progression-free survival (PFS) and overall survival (OS) in relation to metabolic parameters were examined using the Kaplan-Meier method. Results During a median follow-up period of 14.2 months, 43 patients (64.2%) experienced tumor recurrence or progression, and 38 patients (56.7%) died of cancer. In the univariate Cox regression analysis, liver parenchymal invasion (P=0.001), lymph node metastasis (P=0.007), distant metastases (P=0.049), tumor differentiation (P=0.028), surgery (P=0.014), carcinoembryonic antigen (CEA) level (P=0.030), carbohydrate antigen 19-9 (CA19-9) level (P=0.003), TLG (P=0.005), MTV (P<0.001), sum of the TLGs of the primary and metastatic lesions (total TLG, tTLG) (P=0.001), and sum of the MTVs of the primary and metastatic lesions (total MTV, tMTV) (P<0.001) were significant predictors of PFS. In multivariate analysis, MTV was an independent predictor of PFS [hazard ratio (HR) =2.785; 95% confidence interval (CI): 1.204–6.441; P=0.017]. In the univariate Cox regression analysis, liver parenchymal invasion (P=0.001), lymph node metastasis (P=0.027), distant metastases (P=0.036), tumor differentiation (P=0.047), surgery (P=0.002), neutrophil-to-lymphocyte ratio (NLR) (P=0.011), CEA level (P=0.036), CA19-9 level (P<0.001), TLG (P=0.007), MTV (P<0.001), tTLG (P=0.003), and tMTV (P<0.001) were significant predictors of OS. In the multivariate analysis, higher CA19-9 levels >37 U/mL and a greater tMTV (HR =2.961; 95% CI: 1.092–8.024; P=0.033) were predictive of OS. Conclusions Our study results suggest that pretreatment 2-[ 18 F]FDG PET parameters can not only assist in the diagnosis of patients with GBA but may also serve as predictive factors for the prognosis of these patients and should thus be applied in their treatment.

show abstract

A novel nomogram based on log odds of positive lymph nodes to predict survival for non-metastatic gallbladder adenocarcinoma after surgery

Cited by 12 publications

References 31 publications

Predicting hospital readmissions in patients receiving novel-dose Sacubitril/Valsartan therapy: A competing-risk, causal mediation analysis

Predicting hospital readmissions in patients receiving novel-dose Sacubitril/Valsartan therapy: A competing-risk, causal mediation analysis

Development and validation of a web-based nomogram for predicting cancer-specific survival in patients with intrahepatic cholangiocarcinoma: A SEER database analysis

Metabolic parameters of pretreatment 2-[18F]fluoro-D-glucose positron emission tomography for prognosis in patients with gallbladder adenocarcinoma: a cohort study

Contact Info

Product

Resources

About